This functional interaction in between the serotoninergic and central dopaminergic devices continues to be demonstrated in experiments with haloperidol, a D2 receptor antagonist that attenuates the psychotomimetic outcomes of psilocybin [five]. Louisiana law prohibits psilocybin beneath the group